Company intelligence / Profile preview

Infectex

Ownership: Private
Development stage: Other

Overview

Infectex is developing small molecule drugs for infectious diseases. Its lead program, SQ-109 targeting MmpL3, is in Phase 3 for pulmonary tuberculosis. Telacebec, targeting CMV DNA terminase, has reached Phase 2 for Buruli ulcer. Programs have also been explored for Helicobacter pylori and COVID-19, though these indications are inactive.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Sequella, Inc. (SQ-109 compound originator)Qurient Co., Ltd. (Telacebec originator)

Beyond the preview

Go deeper on Infectex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Infectex.